Not-for-profit gets tuberculosis drug approved ahead of big pharmaThe FDA has approved a new drug to treat certain types of multi-drug resistant tuberculosis – but it’s Share XNot-for-profit gets tuberculosis drug approved ahead of big pharmahttps://pharmaphorum.com/news/not-for-profit-tb-alliance-gets-new-tb-drug-approved/
UK government prepares no-deal Brexit express medicines serviceThe UK’s Department of Health and Social Care is setting up a service to deliver emergency medicines into Share XUK government prepares no-deal Brexit express medicines servicehttps://pharmaphorum.com/news/uk-government-prepares-no-deal-express-medicines-service/
Gates Foundation hires Apple digital health expertThe Bill & Melinda Gates Foundation has snapped up one of Apple’s digital health gurus, Dr Andrew Trister, Share XGates Foundation hires Apple digital health experthttps://pharmaphorum.com/news/gates-foundation-hires-apple-digital-health-expert/
FDA approves Roche’s “tumour agnostic” drug RozlytrekThe FDA has approved Roche’s Rozlytrek (entrectinib), a so-called “tumour agnostic” drug that is approved to key into certain mutations in Share XFDA approves Roche’s “tumour agnostic” drug Rozlytrekhttps://pharmaphorum.com/news/fda-approves-roches-tumour-agnostic-drug-rozlytrek/
Scotland’s cost regulator rejects Vertex cystic fibrosis drugsScotland’s cost-effectiveness body has rejected regular NHS funding for Vertex’s cystic fibrosis drugs Orkambi and Symkevi because of Share XScotland’s cost regulator rejects Vertex cystic fibrosis drugshttps://pharmaphorum.com/news/scotlands-cost-regulator-rejects-vertex-cystic-fibrosis-drugs/
Regeneron preps for 2020 filing for new cholesterol drug after trial successRegeneron has announced data that could create a niche for its latest cholesterol drug evinacumab in a small Share XRegeneron preps for 2020 filing for new cholesterol drug after trial successhttps://pharmaphorum.com/news/evinacumab-regeneron-cholesterol-drug-trial/
Novartis axed Avexis execs ahead of Zolgensma scandalThe plot thickens at Novartis, which is becoming embroiled in a scandal over falsification of data related to Share XNovartis axed Avexis execs ahead of Zolgensma scandalhttps://pharmaphorum.com/news/novartis-axed-avexis-execs-ahead-of-zolgensma-scandal/
Astellas tests gamification ideas with Japanese universitiesAstellas has teamed up with Tokyo University of the Arts and Yokohama City University to create and commercialise Share XAstellas tests gamification ideas with Japanese universitieshttps://pharmaphorum.com/news/astellas-tests-gamification-ideas-with-japanese-universities/
AbbVie/Janssen win EU approval for two new Imbruvica usesEuropean regulators have approved AbbVie and Janssen’s Imbruvica (ibrutinib) in two expanded uses that broaden the use of Share XAbbVie/Janssen win EU approval for two new Imbruvica useshttps://pharmaphorum.com/news/eu-regulators-approve-two-new-uses-for-janssens-imbruvica/
